×
News Home

Should You Sell Cara Therapeutics Inc (CARA) in Biotechnology Industry?

Tuesday, January 18, 2022 02:47 PM | InvestorsObserver Analysts
Should You Sell Cara Therapeutics Inc (CARA) in Biotechnology Industry?

Cara Therapeutics Inc (CARA) is around the top of the Biotechnology industry according to InvestorsObserver. CARA received an overall rating of 47, which means that it scores higher than 47 percent of all stocks. Cara Therapeutics Inc also achieved a score of 78 in the Biotechnology industry, putting it above 78 percent of Biotechnology stocks. Biotechnology is ranked 105 out of the 148 industries.

Overall Score - 47
CARA has an Overall Score of 47. Find out what this means to you and get the rest of the rankings on CARA!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Cara Therapeutics Inc Stock Today?

Cara Therapeutics Inc (CARA) stock is trading at $11.68 as of 2:44 PM on Tuesday, Jan 18, a drop of -$0.27, or -2.26% from the previous closing price of $11.95. The stock has traded between $11.60 and $11.97 so far today. Volume today is low. So far 230,739 shares have traded compared to average volume of 450,409 shares. Click Here to get the full Stock Report for Cara Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App